{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:59:09Z","timestamp":1760241549538,"version":"build-2065373602"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Science and Technology Project of Jilin Provincial Education Department","award":["JJKH20221047KJ"],"award-info":[{"award-number":["JJKH20221047KJ"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01516-9","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:57:56Z","timestamp":1759294676000},"page":"981-990","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the anti-leukemia activity and underlying mechanisms of the novel perinucleolar compartment inhibitor CTI-2 in acute myeloid leukemia"],"prefix":"10.1007","volume":"43","author":[{"given":"Anran","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingmin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangshuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"1","key":"1516_CR1","doi-asserted-by":"publisher","first-page":"2196482","DOI":"10.1080\/16078454.2023.2196482","volume":"28","author":"MZ Mohamed Jiffry","year":"2023","unstructured":"Mohamed Jiffry MZ, Kloss R, Ahmed-Khan M, Carmona-Pires F, Okam N, Weeraddana P et al (2023) A review of treatment options employed in relapsed\/refractory AML. Hematology 28(1):2196482. https:\/\/doi.org\/10.1080\/16078454.2023.2196482","journal-title":"Hematology"},{"issue":"22","key":"1516_CR2","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A et al (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059\u20132074. https:\/\/doi.org\/10.1056\/NEJMoa1301689","journal-title":"N Engl J Med"},{"issue":"4","key":"1516_CR3","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1182\/blood.V82.4.1110.1110","volume":"82","author":"O Rosnet","year":"1993","unstructured":"Rosnet O, Schiff C, P\u00e9busque MJ, Marchetto S, Tonnelle C, Toiron Y et al (1993) Human FLT3\/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 82(4):1110\u20131119","journal-title":"Blood"},{"key":"1516_CR4","doi-asserted-by":"publisher","first-page":"1391743","DOI":"10.3389\/fonc.2024.1391743","volume":"14","author":"E Diral","year":"2024","unstructured":"Diral E, Furnari G, Bruno A, Greco R, Clerici D, Marktel S et al (2024) Sorafenib maintenance in FLT3-ITD mutated AML after allogeneic HCT: a real-world, single-center experience. Front Oncol 14:1391743. https:\/\/doi.org\/10.3389\/fonc.2024.1391743","journal-title":"Front Oncol"},{"issue":"2","key":"1516_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y (2020) FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci 111(2):312\u2013322. https:\/\/doi.org\/10.1111\/cas.14274","journal-title":"Cancer Sci"},{"issue":"6","key":"1516_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/cco.0000000000001094","volume":"36","author":"S Travaglini","year":"2024","unstructured":"Travaglini S, Gurnari C, Ottone T, Voso MT (2024) Advances in the pathogenesis of FLT3 -mutated acute myeloid leukemia and targeted treatments. Curr Opin Oncol 36(6):569\u2013576. https:\/\/doi.org\/10.1097\/cco.0000000000001094","journal-title":"Curr Opin Oncol"},{"key":"1516_CR7","doi-asserted-by":"publisher","unstructured":"Frankowski KJ, Wang C, Patnaik S, Schoenen FJ, Southall N, Li D et al (2018) Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Sci Transl Med 10(441). https:\/\/doi.org\/10.1126\/scitranslmed.aap8307","DOI":"10.1126\/scitranslmed.aap8307"},{"key":"1516_CR8","doi-asserted-by":"publisher","unstructured":"Ke J, Han W, Meng F, Guo F, Wang Y, Wang L (2021) CTI-2 inhibits metastasis and epithelial-mesenchymal transition of breast Cancer cells by modulating MAPK signaling pathway. Int J Mol Sci 22(22). https:\/\/doi.org\/10.3390\/ijms222212229","DOI":"10.3390\/ijms222212229"},{"issue":"2","key":"1516_CR9","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/0008-5472.Can-09-2918","volume":"70","author":"B Kumar","year":"2010","unstructured":"Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB et al (2010) p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res 70(2):832\u2013841. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-2918","journal-title":"Cancer Res"},{"issue":"2","key":"1516_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1124\/mol.113.090365","volume":"85","author":"FM Gurgis","year":"2014","unstructured":"Gurgis FM, Ziaziaris W, Munoz L (2014) Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting. Mol Pharmacol 85(2):345\u2013356. https:\/\/doi.org\/10.1124\/mol.113.090365","journal-title":"Mol Pharmacol"},{"issue":"12","key":"1516_CR11","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.bcp.2010.07.039","volume":"80","author":"LS Chen","year":"2010","unstructured":"Chen LS, Balakrishnan K, Gandhi V (2010) Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem Pharmacol 80(12):1936\u20131945. https:\/\/doi.org\/10.1016\/j.bcp.2010.07.039","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1516_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12967-017-1287-4","volume":"15","author":"H Cheng","year":"2017","unstructured":"Cheng H, Huang C, Xu X, Hu X, Gong S, Tang G et al (2017) PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia. J Translational Med 15(1):179. https:\/\/doi.org\/10.1186\/s12967-017-1287-4","journal-title":"J Translational Med"},{"issue":"1","key":"1516_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12943-023-01721-1","volume":"22","author":"M Bellon","year":"2023","unstructured":"Bellon M, Nicot C (2023) Targeting pim kinases in hematological cancers: molecular and clinical review. Mol Cancer 22(1):18. https:\/\/doi.org\/10.1186\/s12943-023-01721-1","journal-title":"Mol Cancer"},{"issue":"7","key":"1516_CR14","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1182\/blood-2005-02-0734","volume":"106","author":"H Luo","year":"2005","unstructured":"Luo H, Li Q, O\u2019Neal J, Kreisel F, Le Beau MM, Tomasson MH (2005) c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood 106(7):2452\u20132461. https:\/\/doi.org\/10.1182\/blood-2005-02-0734","journal-title":"Blood"},{"issue":"21","key":"1516_CR15","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1038\/sj.onc.1205400","volume":"21","author":"B Hoffman","year":"2002","unstructured":"Hoffman B, Amanullah A, Shafarenko M, Liebermann DA (2002) The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21(21):3414\u20133421. https:\/\/doi.org\/10.1038\/sj.onc.1205400","journal-title":"Oncogene"},{"issue":"1","key":"1516_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","volume":"19","author":"R Dhanasekaran","year":"2022","unstructured":"Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW (2022) The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol 19(1):23\u201336. https:\/\/doi.org\/10.1038\/s41571-021-00549-2","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1516_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12094-012-0926-8","volume":"15","author":"MD Delgado","year":"2013","unstructured":"Delgado MD, Albajar M, Gomez-Casares MT, Batlle A, Le\u00f3n J (2013) MYC oncogene in myeloid neoplasias. Clin Transl Oncol 15(2):87\u201394. https:\/\/doi.org\/10.1007\/s12094-012-0926-8","journal-title":"Clin Transl Oncol"},{"key":"1516_CR18","doi-asserted-by":"publisher","unstructured":"Kalkat M, De Melo J, Hickman KA, Lourenco C, Redel C, Resetca D et al (2017) MYC deregulation in primary human cancers. Genes (Basel) 8(6). https:\/\/doi.org\/10.3390\/genes8060151","DOI":"10.3390\/genes8060151"},{"issue":"1","key":"1516_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/10428194.2018.1464158","volume":"60","author":"M Ohanian","year":"2019","unstructured":"Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T et al (2019) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma 60(1):37\u201348. https:\/\/doi.org\/10.1080\/10428194.2018.1464158","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"1516_CR20","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1182\/blood.2020006374","volume":"136","author":"E Bulaeva","year":"2020","unstructured":"Bulaeva E, Pellacani D, Nakamichi N, Hammond CA, Beer PA, Lorzadeh A et al (2020) MYC-induced human acute myeloid leukemia requires a continuing IL-3\/GM-CSF costimulus. Blood 136(24):2764\u20132773. https:\/\/doi.org\/10.1182\/blood.2020006374","journal-title":"Blood"},{"issue":"5","key":"1516_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/1947601911416357","volume":"2","author":"B Salvatori","year":"2011","unstructured":"Salvatori B, Iosue I, Djodji Damas N, Mangiavacchi A, Chiaretti S, Messina M et al (2011) Critical role of c-Myc in Acute myeloid leukemia involving direct regulation of miR-26a and histone methyltransferase EZH2. Genes Cancer 2(5):585\u2013592. https:\/\/doi.org\/10.1177\/1947601911416357","journal-title":"Genes Cancer"},{"issue":"1","key":"1516_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12943-020-01291-6","volume":"20","author":"SK Madden","year":"2021","unstructured":"Madden SK, de Araujo AD, Gerhardt M, Fairlie DP, Mason JM (2021) Taking the myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. Mol Cancer 20(1):3. https:\/\/doi.org\/10.1186\/s12943-020-01291-6","journal-title":"Mol Cancer"},{"issue":"5","key":"1516_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41419-020-2563-4","volume":"11","author":"SJ Wei","year":"2020","unstructured":"Wei SJ, Nguyen TH, Yang IH, Mook DG, Makena MR, Verlekar D et al (2020) MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. Cell Death Dis 11(5):368. https:\/\/doi.org\/10.1038\/s41419-020-2563-4","journal-title":"Cell Death Dis"},{"issue":"35","key":"1516_CR24","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1038\/onc.2008.123","volume":"27","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Wang Z, Li X, Magnuson NS (2008) Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 27(35):4809\u20134819. https:\/\/doi.org\/10.1038\/onc.2008.123","journal-title":"Oncogene"},{"issue":"1","key":"1516_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/carcin\/bgy126","volume":"40","author":"C Zhang","year":"2019","unstructured":"Zhang C, Qie Y, Yang T, Wang L, Du E, Liu Y et al (2019) Kinase PIM1 promotes prostate cancer cell growth via c-Myc-RPS7-driven ribosomal stress. Carcinogenesis 40(1):52\u201360. https:\/\/doi.org\/10.1093\/carcin\/bgy126","journal-title":"Carcinogenesis"},{"issue":"5","key":"1516_CR26","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s12282-019-00966-3","volume":"26","author":"X Gao","year":"2019","unstructured":"Gao X, Liu X, Lu Y, Wang Y, Cao W, Liu X et al (2019) PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation. Breast Cancer 26(5):663\u2013671. https:\/\/doi.org\/10.1007\/s12282-019-00966-3","journal-title":"Breast Cancer"},{"issue":"11\u201312","key":"1516_CR27","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10495-022-01756-7","volume":"27","author":"S Liu","year":"2022","unstructured":"Liu S, Qiao X, Wu S, Gai Y, Su Y, Edwards H et al (2022) c-Myc plays a critical role in the antileukemic activity of the mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia. Apoptosis 27(11\u201312):913\u2013928. https:\/\/doi.org\/10.1007\/s10495-022-01756-7","journal-title":"Apoptosis"},{"issue":"W1","key":"1516_CR28","doi-asserted-by":"publisher","first-page":"W356","DOI":"10.1093\/nar\/gkx374","volume":"45","author":"X Wang","year":"2017","unstructured":"Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X et al (2017) PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res 45(W1):W356\u2013w60. https:\/\/doi.org\/10.1093\/nar\/gkx374","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1516_CR29","doi-asserted-by":"publisher","first-page":"2321265","DOI":"10.1080\/19491034.2024.2321265","volume":"15","author":"M Abou-Ghali","year":"2024","unstructured":"Abou-Ghali M, Lallemand-Breitenbach V (2024) PML Nuclear bodies: the cancer connection and beyond. Nucleus 15(1):2321265. https:\/\/doi.org\/10.1080\/19491034.2024.2321265","journal-title":"Nucleus"},{"issue":"1","key":"1516_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1158\/1078-0432.ccr-17-1629","volume":"24","author":"S Kapoor","year":"2018","unstructured":"Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ et al (2018) Concurrent inhibition of Pim and FLT3 Kinases enhances apoptosis of FLT3-ITD Acute myeloid leukemia cells through increased Mcl-1 proteasomal degradation. Clin cancer Research: Official J Am Association Cancer Res 24(1):234\u2013247. https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-1629","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"4","key":"1516_CR31","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood-2004-05-2006","volume":"105","author":"KT Kim","year":"2005","unstructured":"Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M et al (2005) Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105(4):1759\u20131767. https:\/\/doi.org\/10.1182\/blood-2004-05-2006","journal-title":"Blood"},{"issue":"16","key":"1516_CR32","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1056\/NEJMoa040465","volume":"350","author":"PJ Valk","year":"2004","unstructured":"Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, van Barjesteh S, Boer JM et al (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350(16):1617\u20131628. https:\/\/doi.org\/10.1056\/NEJMoa040465","journal-title":"N Engl J Med"},{"issue":"5","key":"1516_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1365-2141.2007.06696.x","volume":"138","author":"KT Kim","year":"2007","unstructured":"Kim KT, Baird K, Davis S, Piloto O, Levis M, Li L et al (2007) Constitutive fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells. Br J Haematol 138(5):603\u2013615. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06696.x","journal-title":"Br J Haematol"},{"issue":"1","key":"1516_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2141.2007.06525.x","volume":"137","author":"L Li","year":"2007","unstructured":"Li L, Piloto O, Kim KT, Ye Z, Nguyen HB, Yu X et al (2007) FLT3\/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem\/progenitor cells. Br J Haematol 137(1):64\u201375. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06525.x","journal-title":"Br J Haematol"},{"issue":"3","key":"1516_CR35","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/pathophysiology30030031","volume":"30","author":"ZO Doha","year":"2023","unstructured":"Doha ZO, Sears RC (2023) Unraveling MYC\u2019s role in orchestrating Tumor intrinsic and Tumor Microenvironment interactions driving tumorigenesis and drug resistance. Pathophysiology: Official J Int Soc Pathophysiology 30(3):400\u2013419. https:\/\/doi.org\/10.3390\/pathophysiology30030031","journal-title":"Pathophysiology: Official J Int Soc Pathophysiology"},{"key":"1516_CR36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.semcancer.2020.11.008","volume":"83","author":"H Fatma","year":"2022","unstructured":"Fatma H, Maurya SK, Siddique HR (2022) Epigenetic modifications of c-MYC: role in cancer cell reprogramming, progression and chemoresistance. Sem Cancer Biol 83:166\u2013176. https:\/\/doi.org\/10.1016\/j.semcancer.2020.11.008","journal-title":"Sem Cancer Biol"},{"issue":"3","key":"1516_CR37","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3390\/pathophysiology30030024","volume":"30","author":"K Bogdanov","year":"2023","unstructured":"Bogdanov K, Kudryavtseva E, Fomicheva Y, Churkina I, Lomaia E, Girshova L et al (2023) Shift of N-MYC Oncogene expression in AML patients carrying the FLT3-ITD mutation. Pathophysiology 30(3):296\u2013313. https:\/\/doi.org\/10.3390\/pathophysiology30030024","journal-title":"Pathophysiology"},{"issue":"6","key":"1516_CR38","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1074\/jbc.M312241200","volume":"279","author":"JK Brunelle","year":"2004","unstructured":"Brunelle JK, Santore MT, Budinger GR, Tang Y, Barrett TA, Zong WX et al (2004) c-Myc sensitization to oxygen deprivation-induced cell death is dependent on Bax\/Bak, but is independent of p53 and hypoxia-inducible factor-1. J Biol Chem 279(6):4305\u20134312. https:\/\/doi.org\/10.1074\/jbc.M312241200","journal-title":"J Biol Chem"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01516-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01516-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01516-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:04:14Z","timestamp":1760195054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01516-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01516-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Human Ethics Committee of the First Hospital of Jilin University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}